AstraZeneca Sees Strength In Small Molecules, Starts Building Oncology Franchises
With its first oncology approval in 15 years, an imminent submission for its next cancer drug and a slew of trials starting by the end of the year, AstraZeneca is starting to show how oncology will be a growth platform.
You may also be interested in...
Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO.
Failure of Bristol's PD-1 inhibitor Opdivo in first-line lung cancer may open doors for combination use with drugs with immune-activating properties, like prostate cancer drug Xtandi and PARP inhibitor talazoparib.
With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?